Pacira BioSciences, Inc. (PCRX) Form 8-K — Jun 30, 2026
$PCRXForm 8-KItems 1.01, 7.01, 9.01Filed Jun 30, 2026, 7:31 AM ET0001628280-26-046136Original filing
Pacira BioSciences entered into a definitive agreement to divest its iovera business and subsidiary Pacira CryoTech to Zimmer Biomet for up to $140 million. The transaction includes an upfront payment of $70 million, subject to adjustments, plus an additional $70 million in potential milestone payments tied to revenue targets through December 2031.
Key figures
- Deal Value Usd
- $140,000,000
- Upfront Payment
- $70,000,000
- Potential Milestones
- $70,000,000
- Employees Transferred
- 66
- Expected Closing Quarter
- 2026 Q3
- Workforce Percentage Transferred
- 8%
Price after filing
1 day: -1.3%7 days: +1.8%30 days: +4.1%
Close on the filing date to close N calendar days later (from $25.37). Historical, not a forecast.
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.